Europe

Onkodatamed joins Medis

Thursday, March 20, 2014 02:36 PM

Berlin-based clinical research alliance, Medis Research Group, has added Berlin-Brandenburg-based Onkodatamed to its portfolio. Medis Research Group, founded in November, previously consisting only of its two founding members, Allied Clinical Management and ICRC-Weyer, both Berlin-based CROs. The group was formed to better meet requirements of clinical trial sponsors for one-stop shop solutions, hence enabling the two CROs to combine clinical research experience and provide complete service solutions across all stages of the clinical development process.

More... »


Industry reacts to U.K. budget announcement

Thursday, March 20, 2014 01:05 PM

Positive and negative industry responses have surfaced regarding Chancellor George Osborne's budget, from the Ethical Medicines Industry Group (EMIG), the BioIndustry Association (BIA) and the Royal College of General Practitioners (RCGP). The budget includes a $90.9 million establishment of a large-scale cell therapy manufacturing center, an increase in the R&D Tax Credit from 11% to 14.5%, and $175.1 million over five years for doctoral training centers.

More... »


European Medicines Agency launches adaptive licensing pilot project

Thursday, March 20, 2014 01:03 PM

The EMA is inviting companies to participate in its adaptive licensing pilot project. Interested companies should submit ongoing medicine development programs for consideration as prospective pilot cases.

More... »

Teva, NIHR form health research collaboration

Wednesday, March 19, 2014 12:50 PM

Israeli pharmaceutical company Teva will invest $20 million into U.K. clinical trials and $1 million into U.K. dementia research. Teva said it will benefit from the NIHR's translational research infrastructure and its ability to efficiently set up and deliver world-leading health research studies.

More... »

U.K. forms early access to medicines scheme

Monday, March 17, 2014 01:41 PM

The U.K. government has announced a new scheme that aims to give patients with life-threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorization.

More... »

New IMI project to incorporate real-life data into drug development

Thursday, March 13, 2014 12:54 PM

The Innovative Medicines Initiative (IMI) has launched a new project called GETREAL that will investigate new ways to integrate data from real-life settings, such as clinics, into drug development in Europe. This will assist healthcare decision makers in choosing how best to grant patients access to a new treatment and help pharmaceutical companies make better decisions during drug development.

More... »

EFPIA responds to new Clinical Trials regulation

Wednesday, March 12, 2014 02:23 PM

The European Federation of Pharmaceutical Industries and Associations (EFPIA) welcomes the political agreement reached by the European co-­legislators, with the aim of a rapid adoption of the new Regulation on Clinical Trials. However, the original objectives of this legislation should be remembered: to enhance efficiency in the clinical trials regulation process and, in turn, to boost the European Union's competitiveness as a place to conduct research and make for more efficient patients access to new innovative treatments. EFPIA believes some of the initial objectives of the legislation have been only partially achieved; therefore, the success of this legislation strongly depends on how it will apply in practice.  

More... »

MAHSC, Roche partner

Wednesday, March 12, 2014 01:50 PM

Researchers and clinicians from Manchester Academic Health Science Center (MAHSC), a partnership involving the University of Manchester and six NHS Trusts, have launched a major partnership with global pharmaceutical company Roche. The new relationship will boost clinical research studies, which could lead to the development of new drugs and diagnostic tools and give patients in the region greater access to new treatments in development.

More... »

AstraZeneca sells Alderley Park site in Cheshire, U.K.

Wednesday, March 12, 2014 01:41 PM

AstraZeneca has sold its Alderley Park site in Cheshire, U.K., to Manchester Science Parks(MSP), a Greater Manchester-based public-private partnership and science park operator.

More... »

KCR opens new entities in Western Europe

Wednesday, March 5, 2014 01:33 PM

European CRO KCR, which operates across 18 countries in Europe as well as in the U.S., has recently registered new entities in the U.K. and Germany. This move is part of the company’s strategy to bring the business closer to Western European customers and deepen client relationships.

More... »

`

CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs